Comparison of the efficacies of oral iron and pramipexole for the treatment of restless legs syndrome patients with low serum ferritin

被引:32
作者
Lee, C. S. [1 ]
Lee, S. D. [2 ]
Kang, S. -H. [3 ]
Park, H. Y. [1 ]
Yoon, I. -Y. [1 ]
机构
[1] Seoul Natl Univ, Bundang Hosp, Dept Neuropsychiat, Songnam, South Korea
[2] Korean Armed Forces Capital Hosp, Dept Psychiat, Gyeonggi Do, South Korea
[3] Vet Hlth Serv Med Ctr, Dept Psychiat, Seoul, South Korea
关键词
dopamine agonist; ferritin; iron; pramipexole; restless legs syndrome; DOUBLE-BLIND; SYNDROME RLS; HEALTH; TRIAL; PATHOPHYSIOLOGY; AUGMENTATION; HEMODIALYSIS; MULTICENTER; POPULATION; PREVALENCE;
D O I
10.1111/ene.12286
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and purposeIt is not clear which is preferred between iron supplement and a dopamine agonist in the treatment of restless legs syndrome (RLS) with iron deficiency. The efficacies of oral iron supplementation and pramipexole for treatment of RLS with low-normal serum ferritin (15-50ng/ml) were compared. MethodsThirty RLS patients who took either oral iron or pramipexole for 12weeks and were followed at 2, 4, 8 and 12weeks after treatment commencement were enrolled. Severities of RLS symptoms were assessed using the international RLS study group rating scale for severity (IRLS) at every visit. Treatment response was defined as a decrease in IRLS score of at least 50% from baseline. ResultsThe 30 subjects were assigned equally to an iron or pramipexole group. At baseline, IRLS scores and serum ferritin levels were similar between these two groups. After 12weeks, IRLS scores were lower than those at baseline in both groups (iron -9.17.07, P<0.001; pramipexole -8.7 +/- 8.31, P=0.001) and similar between the two groups. Changes in IRLS scores from baseline were similar between the two groups at each visit. The response rates of the groups were identical at 46.7%. ConclusionsPramipexole was not different from oral iron in terms of efficacy and improvement speed in RLS patients with a low-normal serum ferritin, but response rate of either oral iron or pramipexole alone was moderate. Some proportion of RLS patients with iron deficiency might benefit from combined use of oral iron and dopamine agonists.
引用
收藏
页码:260 / 266
页数:7
相关论文
共 30 条
[1]  
Adamson J W., 2008, Harrison Medicina Interna, P628
[2]   Dopamine and iron in the pathophysiology of restless legs syndrome (RLS) [J].
Allen, R .
SLEEP MEDICINE, 2004, 5 (04) :385-391
[3]   Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology - A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health [J].
Allen, RP ;
Picchietti, D ;
Hening, WA ;
Trenkwalder, C ;
Walters, AS ;
Montplaisi, J .
SLEEP MEDICINE, 2003, 4 (02) :101-119
[4]   Restless legs syndrome prevalence and impact - REST general population study [J].
Allen, RP ;
Walters, AS ;
Montplaisir, J ;
Hening, W ;
Myers, A ;
Bell, TJ ;
Ferini-Strambi, L .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (11) :1286-1292
[5]   Restless legs syndrome - A review of clinical and pathophysiologic features [J].
Allen, RP ;
Earley, CJ .
JOURNAL OF CLINICAL NEUROPHYSIOLOGY, 2001, 18 (02) :128-147
[6]  
Aurora RN, 2012, SLEEP, V35, P1039, DOI 10.5665/sleep.1988
[7]   A randomized, double-blind placebo-controlled trial of iron in restless legs syndrome [J].
Davis, BJ ;
Rajput, A ;
Rajput, ML ;
Aul, EA ;
Eichhorn, GR .
EUROPEAN NEUROLOGY, 2000, 43 (02) :70-75
[8]   A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome [J].
Earley, Christopher J. ;
Horska, Alena ;
Mohamed, Mona A. ;
Barker, Peter B. ;
Beard, John L. ;
Allen, Richard P. .
SLEEP MEDICINE, 2009, 10 (02) :206-211
[9]  
Earley CJ, 2000, J NEUROSCI RES, V62, P623, DOI 10.1002/1097-4547(20001201)62:5<623::AID-JNR1>3.3.CO
[10]  
2-8